Loading...

IOBT IO BIOTECH INC US FDA Inspections 8-K Filing

BTC

BT

IO BIOTECH INC

(IOBT)

2024 8-K

Management Change

Investor Conference Update

Financial Results

Restructuring Plan

Financial Results Report

Equity Offerings

Financial Statements

Equity Offerings

Financial Update

Nasdaq Compliance Notice

Financing Agreement

Bylaw Amendments

Financial Results

Trial Continuation

Financial Results

Annual Meeting of Stockholders

Financial Results Announcement

Earnings Reports

Participation in Conference

Financial Results and Appoi...

Financial Results and Direc...

Private Placement

Clinical Trial Expansion

Annual Meeting of Stockholders

Earnings Reports

Resignation of Director

Earnings Reports

Results of Operations and F...

Regulation FD Disclosure

Financial Condition

External Links:

IO Biotech announced that an Independent Data Monitoring Committee recommended continuing its Phase 3 trial of the cancer vaccine IO102-IO103 combined with KEYTRUDA, noting no new safety concerns and projecting the primary endpoint of progression-free survival to be reached in the first half of 2025.

AI Assistant

IO BIOTECH INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.